|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Serum markers detect the presence of liver fibrosis: A cohort study显示文摘 | William M.C. Rosenberg Michael Voelker Robert Thiel Michael Becka Alastair Burt Detlef Schuppan Stefan Hubscher Tania Roskams Massimo Pinzani Michael J.P. Arthur | 2004 | Gastroenterology2004，，6： | 2 |
| 2 | Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7959 ) in heahhy subjects显示文摘 | Kubitza D Becka M Zuehlsdorf M | 2007 | J Clin Pharmacol2007，47，2： | 1 |
| 3 | Safety,pharmacodynamics,and pharmacokinetics of single doses of BAY 59-7939,an oral,direct factor Xa inhibitor显示文摘 | Kubitza D Becka M Voith B | | 0，，： | 1 |
| 4 | Dynamic ordering for a parallel bloek- Jacobi SVD algorithm 显示文摘 | Becka M Oksa G Vajtersic M | 2002 | Parallel Computing2002，28，： | 1 |
| 5 | Safety, tolerability, phar- macodynamics, and pharmacokinetics of rivaroxaban-an oral, di- rect Factor Xa inhibitor-are not affected by aspirin 显示文摘 | Kubitza D Becka M Mueck W | 2006 | J Clin Pharmacol2006，46，9： | 1 |
| 6 | DeNOx reactions on Cu-zeolites Decomposition of NO, N2O and SCR of NO by C3H8 and CH4 on Cu-ZSM-5and Cu-AlTS-1catalysts 显示文摘 | Schay Z Guczi L Becka A | 2002 | Catalysis Today2002，75，14： | 1 |
| 7 | No interaction between the novel oral direct factor Xa inhibitor BAY 59-7939 and digoxin 显示文摘 | Kubitza D Mueck W Becka M | 2006 | J Clin Phann2006，46，3： | 1 |
| 8 | Automated assays of serum markers of liver fibrosis predict histological hepatic fibrosis显示文摘 | RosenbergW Burt A Becka M | 2000 | Hepatology2000，32，： | 1 |
| 9 | High temperature lead-free solder for microelectronics 显示文摘 | Framl W Gau e Gary Becka Jerry Badgett | 2001 | J Electron Mater2001，，6： | 1 |
| 10 | Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects 显示文摘 | Kubitza D Becka M Zuehlsdorf M | 2007 | J Clin Pharmacol2007，47，2： | 1 |
| 11 | Reliability and lifetime evaluation of different wire bonding technologies for high power IGBT modules显示文摘 | A Hamidia N Becka K Thomasb E Herrb | | 0，，05： | 1 |
| 12 | Afastiterativeshrinkagethresholdingalgorithmforlinearinverseproblem显示文摘 | BECKA TEBOULLEM | 2009 | SIAM JournalonImagingSciences2009，2，1： | 1 |
| 13 | Safety, pharmaco- dynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor X a inhibitor--after multiple dosing in healthy male subjects 显示文摘 | Kubitza D Becka M Wensing G | 2005 | Eur J Clin Pharmacol2005，61，： | 1 |
| 14 | Serum markers detect the presence of liver fibrosis: A cohort study显示文摘 | William M.C. Rosenberg Michael Voelker Robert Thiel Michael Becka Alastair Burt Detlef Schuppan Stefan Hubscher Tania Roskams Massimo Pinzani Michael J.P. Arthur | 2004 | Gastroenterology2004，，6： | 1 |
| 15 | Safety, tolerabil- ity, pharmacodynamics, and pharmacokinetics of rivaroxa- ban--an oral, direct factor Xa inhibitor--are not affected by aspirin 显示文摘 | KUBITZA D BECKA M MUECK W | 2006 | J Clin Pharmacol2006，46，9： | 1 |
| 16 | Automated assays of serum markers of liver fibrosis predict histologic hepatic fibrosis显示文摘 | Rosenberg W Burt A Becka M | | 0，，： | 1 |
| 17 | Safety, pharmaco- dynamics, and pharmacokinetics of single doses of BAY 59-7939 an oral, direct factor X a inhibitor 显示文摘 | Kubitza D Becka M Voith B | 2005 | Clin Pharmacol Ther2005，78，4： | 1 |
| 18 | Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban -- an oral direct factor Xa inhibitor -- in healthy subjects 显示文摘 | Mueck W Becka M Kubitza D | 2007 | Int J Clin Pharmacol Ther2007，45，33： | 1 |
| 19 | Safety, pharma- codynamics, and pharmacokinetics of BAY 59-7939 an o- ral, direct factor X a inhibitor - after multiple dosing in healthy male subjects 显示文摘 | Kubitza D Becka M Wensing G | 2005 | Eur J Clin Pharmacol2005，61，12： | 1 |
| 20 | Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban ( BAY 59-7939 ) in healthy subjects显示文摘 | KUBITZA D BECKA M ZUEHLSDORF M | 2007 | J Clin Pharmacol2007，47，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员